Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 18:15:1486422.
doi: 10.3389/fphar.2024.1486422. eCollection 2024.

Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system

Yanjun Lu  1 , Qian Xu  1 , Shita Zhu  1
Affiliations

Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system

Yanjun Lu et al. Front Pharmacol. .

Abstract

Background: This study aims to investigate adverse drug reaction signals associated with coagulopathies through data mining using the Adverse Event Reporting System (FAERS) of the US Food and Drug Administration. Prompt identification of high-risk drugs provides a valuable basis for enhancing clinical drug safety.

Methods: The adverse event reports related to coagulopathies from Q1 2004 to Q2 2024 were extracted from the ASCII data packages in FAERS. The reporting odds ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural network (BCPNN) were used to identify adverse drug reaction signals associated with coagulopathies.

Results: During the reporting period, 40,545 reports were retrieved, with a slightly higher proportion of females than males. Among the top 30 drugs associated with the occurrence of coagulopathies, 24 drugs exhibited positive signals in risk analysis. Based on the individual drug reporting odds ratio (95% confidence interval) as a measure of risk signal strength, the top five drugs are as follows: gemcitabine [ROR (95% CI):16.87 (15.83-17.98)], busulfan [ROR (95% CI):15.51 (13.69-17.58)], anti-thymocyte globulin [ROR (95% CI):15.49 (13.49-17.78)], tacrolimus [ROR (95% CI):12.7 (11.57-13.95)], etonogestrel and ethinylestradiol vaginal ring [ROR (95% CI):11.88 (10.95-12.89)]. After categorizing the drugs, the strongest risk signal is sex hormones and modulators of the genital system [ROR (95% CI):11.88 (10.95-12.89)], followed by analgesics [ROR (95%CI): 6.73 (6.38-7.1)], immunosuppressants [ROR (95% CI):3.91 (3.76-4.05)], antineoplastic agents [ROR (95% CI):3.33 (3.22-3.45)], corticosteroids for systemic use [ROR (95% CI): 2.94 (2.73-3.18)], antiepileptics [ROR (95% CI):1.93 (1.71-2.18)], drugs used in diabetes [ROR (95% CI):1.5 (1.34-1.67)], antibacterials for systemic use [ROR (95% CI):1.46 (1.28-1.68)].

Conclusion: Our findings indicate that multiple drugs are associated with an increased risk of coagulopathies. From the pharmacovigilance perspective, proactive analysis of these drugs aids in clinical monitoring and enhances risk identification of coagulopathies.

Keywords: FAERS database; adverse event; coagulopathies; data mining; disproportionality analyses; pharmacovigilance.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Flow chart for identifying suspected coagulopathies reports.
FIGURE 2
FIGURE 2
Annual trend in reporting of adverse drug events related to coagulopathies.
FIGURE 3
FIGURE 3
ROR for coagulopathies of single drug.
FIGURE 4
FIGURE 4
ROR for coagulopathies of each group of drugs.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Aklilu A. M., Shirali A. C. (2023). Chemotherapy-associated thrombotic microangiopathy. Kidney360 4 (3), 409–422. 10.34067/kid.0000000000000061 - DOI - PMC - PubMed
    1. Alenzi K. A., Alsuhaibani D., Batarfi B., Alshammari T. M. (2024). Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database. Front. Pharmacol. 15, 1364110. 10.3389/fphar.2024.1364110 - DOI - PMC - PubMed
    1. Al-Nouri Z. L., Reese J. A., Terrell D. R., Vesely S. K., George J. N. (2015). Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood 125 (4), 616–618. 10.1182/blood-2014-11-611335 - DOI - PMC - PubMed
    1. Apte R. S., Chen D. S., Ferrara N. (2019). VEGF in signaling and disease: beyond discovery and development. Cell 176 (6), 1248–1264. 10.1016/j.cell.2019.01.021 - DOI - PMC - PubMed
    1. Bartoszko J., Karkouti K. (2021). Managing the coagulopathy associated with cardiopulmonary bypass. J. Thrombosis Haemostasis 19 (3), 617–632. 10.1111/jth.15195 - DOI - PubMed

LinkOut - more resources